THE USE OF PHYSIOLOGICALLY-BASED MODELS TO SIMULATE ENANTIOSELECTIVE DIFFERENCES IN PHARMACOKINETICS

被引:0
|
作者
PIOTROVSKIJ, VK
SHVATCHKO, EV
TRNOVEC, T
机构
[1] INST PREVENT & CLIN MED,BRATISLAVA,SLOVAKIA
[2] CTR PREVENT MED,MOSCOW,RUSSIA
关键词
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS; PHARMACOKINETICS; ENANTIOSELECTIVITY; PREDICTION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The majority of synthetic drugs are chiral and are usually administered as racemates. However, body proteins can recognise the steric configuration, and the pharmacological activity and pharmacokinetics of enantiomers usually differ. The key parameters that determine the overall enantioselectivity in disposition are those quantifying protein binding and biotransformation of drugs. Physiologically based models (PBMs) are effectively applied to predict pharmacokinetics of drugs using the parameters. In this work we used PMB to evaluate a range of changes in the model-independent pharmacokinetic parameters (total clearance, mean residence time, volume of distribution, half-life) with changing relative fraction of enantiomers unbound in the blood (range 1-8) and relative intrinsic hepatic clearance (range 1-10). A pharmacokinetic interaction between enantiomers was also simulated and it was shown the experiments with separate administration of pure enantiomers and of a racemate are equally important to avoid biases in pharmacokinetic parameter estimates due to interactions between enantiomers. Concentration-effect relationships were analyzed for the case of one enantiomer being active, and it was demonstrated that hysteresis as well as proteins may appear depending on the differences in hepatic intrinsic clearances of enantiomers of fractions unbound in blood. The great predictive potential of physiologically based models in stereopharmacokinetics was thereby demonstrated.
引用
收藏
页码:263 / 269
页数:7
相关论文
共 50 条
  • [31] Physiologically-based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimens
    Adiwidjaja, Jeffry
    Gross, Annette S.
    Boddy, Alan, V
    McLachlan, Andrew J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (04) : 1735 - 1750
  • [32] DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL TO UNDERSTAND THE NONLINEAR PHARMACOKINETICS OF LETERMOVIR AND EXPOSURE DIFFERENCES BETWEEN POPULATIONS
    Chen, Dapeng
    Hartmann, Georgy
    Menzel, Karsten
    Cho, Carolyn
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S36 - S36
  • [33] COMBINED USE OF POPULATION AND PHYSIOLOGICALLY-BASED PHARMACOKINETICS TO SUPPORT PEDIATRIC DOSE RECOMMENDATION OF ENTRECTINIB.
    Djebli, N.
    Parrott, N.
    Mercier, F.
    Gonzalez-Sales, M.
    Guerini, E.
    Buchheit, V.
    Berglund, E.
    Bergthold, G.
    Phipps, A.
    Meneses-Lorente, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S10 - S11
  • [34] Development and application of physiologically-based kinetic (PBK) models
    Madden, Judith
    Tan, Yu-Mei
    Blaauboer, Bas
    Paini, Alicia
    Computational Toxicology, 2020, 13
  • [35] An Overview of Physiologically-Based Pharmacokinetic Models for Forensic Science
    Fairman, Kiara
    Choi, Me-Kyoung
    Gonnabathula, Pavani
    Lumen, Annie
    Worth, Andrew
    Paini, Alicia
    Li, Miao
    TOXICS, 2023, 11 (02)
  • [36] INVITRO METABOLISM OF ISOFENPHOS IN HUMAN AND ANIMAL LIVER - USE IN PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELS
    KNAAK, JB
    ALBAYATI, MA
    RAABE, OG
    BLANCATO, JN
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1990, 199 : 112 - AGRO
  • [37] Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development
    Glassman, Patrick M.
    Balthasar, Joseph P.
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : 3 - 13
  • [38] Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies
    Glassman, Patrick M.
    Balthasar, Joseph P.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 (04) : 427 - 446
  • [39] PREDICTION OF ANTICHOLINESTERASE ACTIVITY AND URINARY METABOLITES OF ISOFENPHOS - USE OF A PERCUTANEOUS PHYSIOLOGICALLY-BASED PHARMACOKINETIC PHYSIOLOGICALLY-BASED PHARMACODYNAMIC MODEL
    KNAAK, JB
    ALBAYATI, MA
    RAABE, OG
    BLANCATO, JN
    BIOMARKERS OF HUMAN EXPOSURE TO PESTICIDES, 1994, 542 : 284 - 300
  • [40] Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies
    Patrick M. Glassman
    Joseph P. Balthasar
    Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43 : 427 - 446